We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE
Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada
Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in CanadaView Video
Roundtable Discussion; The Future of Mineral Sands
Roundtable Discussion; The Future of Mineral SandsView Video

Latest Share Chat

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 23.50 (1.38%)
Spread: 1.00 (0.058%)
Open: 1,705.00
High: 1,729.50
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Stocks Slip As Focus Moves To Fed's Yellen

Thu, 25th Aug 2016 16:03

LONDON (Alliance News) - UK equity indices ended lower on Thursday, with pharmaceuticals stocks amongst the biggest blue-chip fallers, as investors look ahead to a speech from US Federal Reserve Chair Janet on Friday at the Jackson Hole conference.

The FTSE 100 closed down 0.3%, or 18.88 points, at 6,816.90. The FTSE 250 ended down 0.7%, or 131.80 points, at 17,882.85, and the AIM All-Share was down 0.3%, or 2.39 points, at 789.67.

The CAC 40 in Paris ended down 0.7% and the DAX 30 in Frankfurt finished down 0.9%.

On Wall Street at the European equity close, the Dow Jones Industrial Average was flat, the S&P 500 was up 0.1% and the Nasdaq Composite was up 0.2%.

Trading volumes have been relatively thin in equity markets in the week so far as investors await Yellen's speech on Friday at 1500 BST. Investors will keep a close eye on her remarks for clues about the outlook for US interest rates, but the Fed Chair is likely to indicate that a US rate hike is still data dependent.

On that front, US durable goods data on Thursday afternoon showed a stronger than expected rise in durable goods orders in July.

The Commerce Department said durable goods orders rose by 4.4% in July after declining by a revised 4.2% in June. Economists had expected orders to climb by about 3.7% compared to the 4.0% slump that had been reported for the previous month.

The bigger-than-expected increase in durable goods orders was partly due to a substantial rebound in orders for transportation equipment, which shot up by 10.5% in July, having fallen by 11.4% in June.

"US durable goods data was really smashing and it has made a lot of difference with respect to what Yellen will say tomorrow," commented Naeem Aslan, chief market analyst at Think Markets. "The data released today has confirmed that we are standing on solid foundations."

At the London stock market close, the pound traded the dollar at USD1.3192, compared to the USD1.3227 seen at the close on Wednesday.

The euro traded the greenback at USD1.1279, largely unchanged from the USD1.1246 at the close on Wednesday.

On the London Stock Exchange, pharmaceutical stocks ended lower after presidential nominee Hillary Clinton raised concerns about the price increase of an allergy product by US pharmaceutical company Mylan.

The price of the company's EpiPen product has risen by 480% since the company acquired it in 2007, moving from USD100 for a 2-pack in 2007 to its current cost of around USD600.

"That's outrageous - and it's just the latest troubling example of a company taking advantage of its consumers," said Clinton in a statement published on her Facebook profile. "It's wrong when drug companies put profits ahead of patients, raising prices without justifying the value behind them."

In response to the growing criticism, Mylan said it would lower the costs of the life-saving treatment for some patients. Mylan said it is taking immediate action to further enhance access to the EpiPen product by expanding already existing programs for patients facing the burden of higher out-of-pocket costs.

Hikma Pharmaceuticals ended as the biggest FTSE 100 faller, down 5.3%, whilst Shire was down 3.0%, AstraZeneca down 1.8%, and GlaxoSmithKline down 0.5%.

CRH ended up 3.4%, the best performer in the FTSE 100, after the Irish building materials company said its profit came in six times higher than a year earlier in its first half, reflecting continued positive momentum in the Americas and the inclusion of acquisitions made in the second half of 2015.

CRH said trading conditions in the first half in Europe reflected the modest impact of early-stage economic recovery.

In the Americas, the company said it expects the positive momentum seen in construction markets during the first half of the year to continue into the second, while in Asia the positive demand backdrop experienced in the Philippines looks set to continue for the rest of the year.

Entertainment One shares sunk after ITV withdrew its proposal to acquire the television and film producer.

ITV made an offer for Entertainment One at 236.00 pence per share, valuing it at around GBP1.03 billion, in early August, but this bid was rebuffed by Entertainment One's board as it said it "fundamentally undervalues" the business.

ITV said Thursday that it has a "clear view of the value" of Entertainment One, and it "appears this value is different to the level at which the board of eOne would currently engage in a more formal process."

The broadcaster said it has a "clear strategy to build a stronger, more diversified international business and will continue its disciplined approach to evaluating its healthy pipeline of potential investment opportunities."

ITV ended down 0.2%, while Entertainment One was the biggest faller in the FTSE 250 index, down 17% to 209.28p.

Infrastructure investor John Laing Group, up 7.4%, said its net asset value rose in the first half of 2016 and maintained its full year guidance for investment commitments.

The company's net asset value per share also rose to 263.00 pence at the end of its first half from 242.00p at the end of December, and 224.00p a year earlier.

"These results demonstrate that our business model is delivering consistent results, and has the ability to cope with today's changing macro-economic environment, including the impact of Brexit," said Chief Executive Olivier Brousse.

The price of gold lost some ground on Thursday, trading at USD1,322.00 an ounce at the London equity market close, versus USD1,327.00 at the same time on Wednesday.

Oil prices, however, moved in the opposite direction, with Brent quoted at USD49.40 a barrel at the close Thursday compared to USD48.75 on Wednesday.

Aside from Yellen's speech on Friday, the focus will be on second quarter GDP readings for the UK at 0930 BST and the US at 1330 BST. Before that is the Japanese consumer price index at 0030 BST, the Gfk consumer confidence survey for Germany at 0700 BST and French GDP at 0745 BST.

At 1330 BST, there are US goods trade balance and personal consumption expenditure prices. The Reuters/Michigan consumer sentiment index is at 1500 BST, and the Baker Hughes US oil rig count is at 1800 BST.

In the UK corporate calendar, casual dining company Restaurant Group, concrete paving manufacturer Marshalls, IT infrastructure company Computacenter, and equipment rental firm Lavendon Group all report interim results.

By Neil Thakrar; neilthakrar@alliancenews.com; @NeilThakrar1

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.